Montréal, Québec, Canada . US Headquarters. Montréal, Québec, Canada . Real-time Price Updates for Theratechnologies (TH-T), along with buy or sell indicators, analysis, charts, historical performance, news and more(2018-03-06 | TSX:TH) Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzo™ (ibalizumab-uiyk) Injection, the First HIV-1 Inhibitor and Long-Acting Monoclonal Antibody for Multidrug Resistant HIV-1. Visit the TSX ETF Investor Centre to access our screener and comparison tool. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . T. By continuing to use our service, you agree to our use of cookies. 36 morning pop. . TH1902 is a first-in-class PDC targeting SORT1, that consists of 2 molecules of docetaxel attached to the TH19P01 peptide via a cleavable succinyl linker. US Headquarters. Theratechnologies Inc. View real-time stock prices and stock quotes for a full financial overview. com uses cookies on this site. Stockhouse. (2022-05-31 | TSX:TH) Theratechnologies Announces New Head of Investor Relations. During the last trading day the stock fluctuated 12. Cookies are used to offer you a better browsing experience and to analyze our traffic. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. European Headquarters. 03) EPS for the quarter, beating the consensus estimate of ($0. THERATECHNOLOGIES INC. 514-336-7800. (2013-04-03 | TSX:TH) Theratechnologies Inc. Headquarters. 65 per cent to C$1. 67% from the latest price. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it plans to pursue Phase 3 clinical development of tesamorelin for the treatment of Non-Alcoholic Steatohepatitis (NASH) in. Senior Director, Communications & Corporate Affairs. 11, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Senior Director, Investor Relations. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. VANCOUVER, British Columbia, Nov. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies,. S. MONTREAL, Nov. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. com. stock news by MarketWatch. 250 Howe Street, Suite 1400 Vancouver, British Columbia, V6C 3S7 Click to expand. - Q3 2022 Consolidated Revenue Growth of 17% to $20. 75%. . Browse posts by Sector and Subsector. Theratechnologies Inc. Ibalizumab-uiyk (Trogarzo) is a medical infusion treatment for HIV infection in adults for whom other HIV medicines have not worked. La Bourse de Toronto a perdu. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from tissue microarrays showing high expression of. E-Poster website launch date and time: Saturday, April 10, 2021, 8:30 AM. TH | May 19, 2023. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. On July 28, 2023, Theratechnologies announced that the Company had entered into an agreement with certain funds and accounts for which Marathon Asset Management, L. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported the voting results from its annual meeting of shareholders held today in a virtual-only setting. 1300 (+9. 22, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Investor Relations. 89 $2. Theratechnologies had a negative net margin of 36. 69, 1. Theratechnologies presented the pre-clinical and clinical data gathered thus far to the SAC, which made recommendations to modify the frequency of administration, selection of tumor types and. We also use them to share usage. MONTREAL, July 23, 2021 /CNW Telbec/ - Theratechnologies Inc. TO) on CEO. 2. (2021-03-20 | TSX:TH) Theratechnologies Announces New Data Demonstrating Tesamorelin's Positive Effect on Immune Response Linked to Liver Inflammation. , a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced further changes to its operations that will see a tapering. Theratechnologies Inc. (TSX: TH, Forum) noted that its Q1 2022 consolidated sales grew 20%, supported by 35% growth in sales of EGRIFTA SV formulation. This news release constitutes a “designated news release” for the purposes of the Company’s. Phone Number (514) 336-7800. 12, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] (TH) has posted net revenue estimates for fourth quarter and the full fiscal year ending Nov 30, 2020. NEW YORK, Dec. 617-356-1009. MONTREAL, Sept. TH | September 26, 2023. (NASDAQ:NASDAQ:THTX) Q1 2021 Earnings Conference Call April 14, 2021 8:30 AM ETCompany ParticipantsDenis Boucher - Vice President,. (TH. [email protected] Inc: Overview. Currency in USD Follow 2W 10W 9M 1. 75. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We currently market prescription products for people with. (“Theratechnologies”, the “Company”, or “we”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has completed the previously announced consolidation of the issued. Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. Betteryear2. MONTREAL, April 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. . Free cash flow. Theratechnologies inc. By continuing to use our service, you agree to our use of cookies. Theratechnologies (TH) has taken home a 2021 ADRIQ Innovation Award in the Life Sciences category. T. Headquarters. Theratechnologies is currently developing a platform of proprietary peptides called SORT1+ Technology TM for cancer drug development targeting SORT1. This news release constitutes a “designated news release” for the purposes of the. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its third quarter of fiscal 2022 ended August 31, on Thursday, October 13. Theratechnologies (TH) provided business highlights and financial results for the second quarter and first half of fiscal year 2022; For the three- and six-month periods ending May 31, 2022, consolidated revenue was US$19,268,000 and US$37,825,000, compared to US$17,787,000 and US$33,217,000 for the same periods last year,. 22M. 4%. Stockhouse. We also use them to share usage information with our partners. Theratechnologies Appoints New Board Member. The company was. Theratechnologies Inc. Theratechnologies Announces 1-for-4 Reverse Stock Split. Investor inquiries: Elif McDonald. By continuing to use our service, you agree to our use of cookies. (2019-08-12 | TSX:TH) Theratechnologies Files Application to List on NASDAQ. Conjugating the short peptide with various anti-cancer agents allows for. We also use them to share usage information with our partners. 5% workforce reduction. TO) Stock Price, News, Quote & History - Yahoo Finance Canada Markets close in 43 mins S&P/TSX 20,125. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Stockhouse. com uses cookies on this site. Gary Littlejohn Stockhouse. Cookies are used to offer you a better browsing experience and to analyze our traffic. Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc. Cenicriviroc (CVC) is a novel, orally administered, chemokine receptor type 2 and 5 antagonist that showed antifibrotic potential in preclinical and phase IIb studies of nonalcoholic steatohepatitis (NASH). By continuing to use our service, you agree to our use of cookies. 11/05/2020 4:15:02 PM. (TSE:TH) posted its quarterly earnings data on Tuesday, September, 26th. Theratechnologies’ R&D staff is bearing the brunt of. Elif McDonald - Senior Director, Investor Relations. com uses cookies on this site. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. - On track to meet FY2022. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. 9 million and US. 4. 60%. Denis Boucher. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 16%. Canada’s largest financial portal for Canadian small-cap investors is right here at Stockhouse where our Bullboards are a leading forum. Montreal-based biopharmaceutical company Theratechnologies Inc. (THTX) Stock Price, Quote & News - Stock Analysis -20. (2022-02-10 | TSX:TH) Theratechnologies to Announce Financial Results for Its Fourth Quarter and Full Fiscal Year 2021. FY2022 top line revenue expected to end the year at ~$80 million, in line with previously announced revenue guidance; FY2023 revenue guidance range set between $90 million and $95 million, ending the new year on a solid path to positive cash. Theratechnologies Announces First Patient Dosed in Phase 1 Clinical Trial of TH1902 for Sortilin Positive Solid Tumors. MONTREAL, Aug. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. Share your ideas and get valuable insights from the community of like minded traders and investors Headquarters. The company's proprietary technologies include Long Acting Peptides, a peptide stabilization technology that. The ADRIQ (Association pour le développement de la recherche et de l’innovation du Québec) rewards Quebec-based companies for leadership and innovation in their respective. (2020-11-03 | TSX:TH) Theratechnologies Announces Departure of Chief Commercial Officer. 04, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. Fri, 17 Apr 2015 15:08:33 GMT ~ Supreme Court of Canada rules in favour of Theratechnologies. (2013-04-03 | TSX:TH) Theratechnologies Inc. We currently market prescription products for people with HIV in the United States. Further. Find the latest Theratechnologies Inc. The Notes were issued under a trust indenture dated as of June 19, 2018, by and among Theratechnologies and Computershare Trust Company of Canada. “This is yet another major achievement for our oncology program. Their average twelve-month price target is $36. Theratechnologies Inc. Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc. Theratechnologies (TH) has submitted a supplemental biologics license application (sBLA) to the U. 9 million, adjusted EBITDA of $2. (THTX) stock quote, history, news and other vital information to help you with your stock trading and investing. Stockhouse. com uses cookies on this site. MONTREAL, Sept. MONTREAL, June 30, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. . Amendment Withdraws the Condition to File HFS Report to the FDA to Access the US$20 Million Second Tranche. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. The FDA granted fast track designation to TH1902 as a single agent for. OTCQX – this is the premium tier of OTC stocks. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. FDA for its IV push form of administration of Trogarzo. T. [email protected] Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update T. Forecast to breakeven in 2024 Jul 15. T. We also use them to share usage. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has established an at-the-market ("ATM") equity program allowing Theratechnologies to. Cookies are used to offer you a better browsing experience and to analyze our traffic. TH | February 28, 2023. 1-438. Stockhouse. The business had revenue of $27. MONTREAL, June 30, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Stock analysis for Theratechnologies Inc (TH:Toronto) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. com uses cookies on this site. The price has fallen in 7 of the last 10 days and is down by -30. About Theratechnologies Theratechnologies (TSX:TH) is a specialty pharmaceutical company addressing unmet medical needs to promote healthy ageing and an improved quality of life among HIV patients. By continuing to use our service, you agree to our use of cookies. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management. TH 48% v4,15M c1. Theratechnologies Inc. 8. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. Volume has increased on the last day along with the price, which is a. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of a notification letter (the “Notification Letter. Cookies are used to offer you a better browsing experience and to analyze our traffic. FAQ – Utilisateurs de TMX Argent NOUVEAU. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the. Theratechnologies Inc. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, Oct. 3 brokerages have issued 1-year price objectives for Theratechnologies' shares. (Image via Theralase Technologies Inc. Theratechnologies inc. TH1902, a newly developed sortilin (SORT1)-targeted peptide-docetaxel conjugate is currently in phase-1 clinical trial. $44. 3089 Background: SORT1 is expressed in a variety of tumors when compared to most healthy tissue. MONTREAL, Feb. Cookies are used to offer you a better browsing experience and to analyze our traffic. com uses cookies on this site. The Company currently commercializes two products in the field of HIV. (2022-09-12 | TSX:TH) Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth. These companies provide a lot of detail to the OTC Markets Group including audited financials. This news release constitutes a “designated news release” for the purposes. Cookies are used to offer you a better browsing experience and to analyze our traffic. Cookies are used to offer you a better browsing experience and to analyze our. GUD | Complete Knight Therapeutics Inc. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ¨ Form 40-F xMain number: 514-336-7800. (2022-07-27 | TSX:TH) Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement Stockhouse. (“Teuton” or “the Company”) (TSXV:TUO) (Frankfurt:TFE) has received news from its joint venture partner, Tudor Gold Corp. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Microsoft to invest $500M in Quebec AI economy. Theratechnologies présente des données démontrant la surexpression de la sortiline (SORT1) dans plusieurs types de tumeurs au 34e symposium de l’EORTC-NCI-AACRVice President, Communications and Corporate Affairs. 25 to $1. (2021-06-30 | TSX:TH) CORRECTION: Theratechnologies to Announce Financial Results for Its Second Quarter Fiscal 2021. $103. : Renegotiated Lease to Generate Substantial Annual Savings Stockhouse. 5%. - Issued and outstanding common shares to be consolidated on the basis of 1 post-consolidation share for each 4 pre-consolidation shares issued and outstanding, to regain compliance with NASDAQ listing requirements. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced preliminary efficacy data from a Phase 1 study of its lead investigational peptide-drug. M. When this page refreshes you will be logged in with the new address. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a commercial-stage biopharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Overview Stock Screener Earnings Calendar Sectors Nasdaq | THTX U. By continuing to use our service, you agree to our use of cookies. com uses cookies on this site. 1. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 ir@theratech. (2019-08-07 | TSX:TH) Jean-Denis Talon Retires From Theratechnologies' Board of Directors. Track Theratechnologies Inc. SORT1 is a “scavenger” receptor that plays a significant role in protein internalization, sorting, and. MONTREAL, July 07, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. CALGARY, AB, May 12, 2022 /PRNewswire/ - Exro Technologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 06 million, an increase of. com uses cookies on this site. 's motion for leave to commence. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. TH | May 19, 2023. Marsolais’ presentation will be available through. RESSOURCES. . T. home message. TORONTO, Sept. B2Gold Declares Fourth Quarter 2023 Dividend. Cookies are used to offer you a better browsing experience and to analyze our traffic. Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 [email protected]%) S&P 500. Share your ideas and get valuable. 19, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. L. 04, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, Feb. Theratechnologies reduces R&D head count to compensate for sales setback. Metastasis is a form of cancer that has spread from its original site to a distant site or organ where it grows or metastasizes. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced an update on the plan to amend and optimize the protocol of its Phase 1 oncology. GlobeNewswire. znewcar1. Theratechnologies inc. Betteryear2. /NOT FOR DISTRIBUTION TO UNITED STATES OF AMERICA WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OF AMERICA/. com uses cookies on this site. (TH. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second quarter. This news release constitutes a "designated news release" for the purposes of. Cookies are used to offer you a better browsing experience and to. VANCOUVER, British Columbia, Nov. This is the list of the largest public listed companies in the Drug Manufacturers—Specialty & Generic industry from Canada by market capitalization with links to their reference stock. By continuing to use our service, you agree to our use of cookies. See a list of the most recent Stock Forum posts on Stockhouse. (THTX) NasdaqCM - NasdaqCM Real Time Price. Cookies are used to offer you a better browsing experience and to analyze our traffic. (TSX-V: TLT, Forum) has demonstrated proof-of-concept for its Canadian-made COVID-19 vaccine. 12, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 2. - 2023 Q3 positive adjusted EBITDA to be. Sol-Gel Technologies (NASDAQ:SLGL) and Theratechnologies (NASDAQ:THTX) are both small-cap medical companies, but which is the better investment?We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, community ranking, risk,. The webinar will also address system-level barriers and present real-world. sBLA for F8 formulation of tesamorelin submitted to FDA. 2022 Revenue Guidance Theratechnologies anticipates fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the. We also use them to share usage. MONTREAL, Aug. Patient assistance: 833-238-4372. 2 million. Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Register for your free account today at data. Theratechnologies Inc. Stockhouse. By continuing to use our service, you agree to our use of cookies. 00. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) today announced the publication of a preclinical study demonstrating the in vitro and in vivo efficacy of TH1902, an investigational sortilin (SORT1)-targeted peptide-drug conjugate, in inhibiting ovarian cancer and triple-negative breast cancer (TNBC. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨Theratechnologies has established its SORT1+ Technology™ platform as an engine for the development of proprietary peptide-drug conjugates (PDCs) that target the sortilin (SORT1) receptor, which is expressed in multiple tumor types. Cookies are used to offer you a better browsing experience and to analyze our traffic. MONTREAL, Jan. 9 million as at August 31, 2023. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. com. L. This module allows you to check different measures of market premium (i. We also use them to share usage information with our partners. Theratechnologies. 28, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. , Senior Vice President and Chief Medical Officer, Theratechnologies commented, “The exciting new data in triple negative breast and ovarian cancer demonstrate. Theratechnologies to Announce Financial Results for Its First Quarter 2022. [at noodls] - Montreal, Canada - April 17, 2015 - Theratechnologies Inc. com uses cookies on this site. View real-time stock prices and stock quotes for a full financial overview. 63. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented preclinical data that demonstrate the potential utility of its lead investigational. For investor inquiries: Leah Gibson. Further. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that President and CEO, Paul Lévesque has issued an open letter to. By continuing to use our service, you agree to our use of cookies. By continuing to use our service, you agree to our use of cookies. T. Volatility Over Time: TH's weekly volatility has increased from 16% to 25% over the past year. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. TH | July 20, 2023. Theratechnologies (TSX:TH)has indicated that Trogarzo did not meet its primary endpoints in its IM method study. GlobeNewswire. $30. Q3 2023 consolidated revenue of $20. 9%, while the Biotechs industry saw earnings growing at 17. " The 12-month stock price forecast is $18. 86%. About Theratechnologies. TH | Complete Theratechnologies Inc. About Theratechnologies. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and. By continuing to use our service, you agree to our use of cookies. D. Christian Marsolais, Ph. 82 million. By continuing to use our service, you agree to our use of cookies. TH1902, the leading product candidate derived from the SORT1+ Technology, is a first-in-class peptide-drug. , that crews have been mobilized to prepare for the 2022 exploration program at the Treaty Creek property, located in the heart of the. First Quarter Fiscal 2022 Financial Results. Cookies are used to offer you a better browsing experience and to. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . TO) stock quote, history, news and other vital information to help you with your stock trading and investing. By continuing to use our service, you agree to our use of cookies. Senior Director, Investor Relations. Theratechnologies Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2023 financial results on Thursday, November 9, 2023 prior to market opening. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. This work is well underway and will be considered by the SAC as part of their meeting, which is scheduled for the latter half of March when the analyses are expected to be ready. By continuing to use our service, you agree to our use of cookies. 66% compared to the previous year's 69. Theratechnologies is leveraging its SORT1+ Technology™ to develop a new class of therapy that targets sortilin (SORT1)-positive cancers by linking anticancer drugs to proprietary peptides that specifically bind to the sortilin receptor. 33. Theratechnologies was founded in 1993 and currently employs more than 150 people in Canada, the United States and Europe. com uses cookies on this site. 00, suggesting a possible upside of. We also use them to share usage information with our partners. – Form 40-F for Fiscal Year Ended November 30, 2011 – Your File No. TMX Group Limited and its affiliates do not endorse or recommend any securities issued by any companies identified on, or linked through, this site. 30, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Inc. 30, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. We also use them to share. Cookies are used to offer you a better browsing experience and to analyze our traffic.